N-glycan structure of a short-lived variant of ribophorin I expressed in the MadIA214 glycosylation-defective cell line reveals the role of a mannosidase that is not ER mannosidase I in the process of glycoprotein degradation

A soluble form of ribophorin I (RI332) is rapidly degraded in Hela and Chinese hamster ovary (CHO) cells by a cytosolic proteasomal pathway, and the N-linked glycan present on the protein may play an important role in this process. Specifically, it has been suggested that endoplasmic reticulum (ER) mannosidase I could trigger the targeting of improperly folded glycoproteins to degradation. We used a CHO-derived glycosylation-defective cell line, MadIA214, for investigating the role of mannosidase(s) as a signal for glycoprotein degradation. Glycoproteins in MadIA214 cells carry truncated Glc(1)Man(5)GlcNAc(2) N-glycans, This oligomannoside structure interferes with protein maturation and folding, leading to an alteration of the ER morphology and the detection of high levels of soluble oligomannoside species caused by glycoprotein degradation. An HA-epitope-tagged soluble variant of ribophorin I (RI332-3HA) expressed in MadIA214 cells was rapidly degraded, comparable to control cells with the complete Glc(3)Man(9)GlcNAc(c) N-glycan, ER-associated degradation (ERAD) of RI332-SHA was also proteasome-mediated in MadIA214 cells, as demonstrated by inhibition of RI332-3HA degradation with agents specifically blocking proteasomal activities. Two inhibitors of alpha1,2-mannosidase activity also stabilized RI332-3HA in the glycosylation-defective cell line. This is striking, because the major mannosidase activity in the ER is the one of mannosidase I, specific for a mannose alpha1,2-linkage that is absent from the truncated Man(5) structure. Interestingly, though the Man, derivative was present in large amounts in the total protein pool, the two major species linked to RI352-3HA shortly after synthesis consisted of Glc(1)Man(5) and Man(4), being replaced by Man(4) and Man(3) when proteasomal degradation was inhibited. In contrast, the untrimmed intermediate of RI332-3HA was detected in mutant cells treated with mannosidase inhibitors. Our results unambiguously demonstrate that an al,2-mannosidase that is not ER mannosidase I is involved in ERAD of RI332-3HA in the glycosylation-defective cell line, MadIA214.